Latest Glatiramer acetate Stories
The monthly injection of GA Depot is intended to replace current treatments for RRMS including the daily or thrice-weekly injection of Copaxone® NESS ZIONA, Israel, December 17, 2014 /PRNewswire/
- Data include post-hoc assessments of controlled studies in relapsing MS regarding evolution of gadolinium-enhancing lesions, assessments of predictive scores for disease activity and disability progression,
~Convening World's Leading Researchers in MS with a Program Covering all Aspects of Research Including Cause and Pathology, Genetics and Environmental Impact, Emerging Treatment Study Findings and
PITTSBURGH, Aug. 28, 2014 /PRNewswire/ -- Mylan Inc.
-- Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs into the Clinic During 2014 -- ROCKVILLE, Md., Aug.
Biogen Idec's Tecfidera is Forecast to Overtake Teva's Copaxone Franchise as the U.S. Market Leader by 2015, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
-- Oral Presentation to Include Greater Detail on Clinical Outcomes, Including Significant and Unique Improvements in Cognition -- ROCKVILLE, Md., July 31, 2014 /PRNewswire/ -- Synthetic
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
NESS ZIONA, Israel, May 27, 2014 /PRNewswire/ -- Mapi Pharma Ltd.
PITTSBURGH, May 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today commented on the ruling by the U.S.
- Emitting flashes of light; glittering.